​

Caris Life Sciences (CAI) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

CAI Stock Forecast

Caris Life Sciences (CAI) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $31.33, with a high of $38.00 and a low of $26.00. This represents a 50.26% increase from the last price of $20.85.

CAI Stock Rating

Caris Life Sciences stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (75.00%), 1 Hold (25.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 1 3 Strong Sell Sell Hold Buy Strong Buy

CAI Price Target Upside V Benchmarks

TypeNameUpside
StockCaris Life Sciences50.26%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts146
Avg Price Target$26.00$30.50$33.17
Last Closing Price$20.85$20.85$20.85
Upside/Downside24.70%46.28%59.09%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Feb, 26171--9
Jan, 26171--9
Dec, 2517---8
Nov, 2517---8
Oct, 2517---8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 17, 2026Robert W. Baird$26.00$20.6226.09%24.70%
Jan 05, 2026Evercore ISI$38.00$26.6842.43%82.25%
Dec 22, 2025Kyle MiksonCanaccord Genuity$30.00$27.947.37%43.88%
Dec 02, 2025Canaccord Genuity$28.00$26.057.49%34.29%
Aug 13, 2025Mark MassaroBTIG$45.00$34.7829.38%115.83%
Jul 13, 2025Subbu NambiGuggenheim$32.00$26.5120.71%53.48%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 13, 2025BTIGBuyBuyhold
Jul 14, 2025Wolfe ResearchOutperforminitialise
Jul 14, 2025CitigroupBuyinitialise
Jul 14, 2025Cowen & Co.Buyinitialise
Jul 13, 2025GuggenheimBuyinitialise

Financial Forecast

EPS Forecast

$-15 $-10 $-5 $0 $5 $10 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 23Dec 24Dec 25Dec 26Dec 27
Reported-----
Avg Forecast$5.71$-10.43-$0.21$0.66
High Forecast$6.84$-10.43-$0.39$0.85
Low Forecast$4.58$-10.43-$0.03$0.29
Surprise %-----

Revenue Forecast

$300M $480M $660M $840M $1B $1B Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 23Dec 24Dec 25Dec 26Dec 27
Reported-----
Avg Forecast$421.94M$452.50M$330.09M$939.25M$1.16B
High Forecast$506.33M$452.50M$330.09M$939.25M$1.16B
Low Forecast$337.55M$452.50M$330.09M$939.25M$1.16B
Surprise %-----

Net Income Forecast

$-200M $-130M $-60M $10M $80M $150M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 23Dec 24Dec 25Dec 26Dec 27
Reported-----
Avg Forecast$123.78M$-187.27M-$3.77M$10.23M
High Forecast$148.53M$-187.27M-$7.00M$15.26M
Low Forecast$99.02M$-187.27M-$538.47K$5.21M
Surprise %-----

CAI Forecast FAQ

Is Caris Life Sciences stock a buy?

Caris Life Sciences stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Caris Life Sciences is a favorable investment for most analysts.

What is Caris Life Sciences's price target?

Caris Life Sciences's price target, set by 4 Wall Street analysts, averages $31.33 over the next 12 months. The price target range spans from $26 at the low end to $38 at the high end, suggesting a potential 50.26% change from the previous closing price of $20.85.

How does Caris Life Sciences stock forecast compare to its benchmarks?

Caris Life Sciences's stock forecast shows a 50.26% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Caris Life Sciences over the past three months?

  • February 2026: 11.11% Strong Buy, 77.78% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 11.11% Strong Buy, 77.78% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.
  • December 2025: 12.50% Strong Buy, 87.50% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Caris Life Sciences’s EPS forecast?

Caris Life Sciences's average annual EPS forecast for its fiscal year ending in December 2023 is $5.71, marking a 0% decrease from the reported - in 2022. Estimates for the following years are $-10.43 in 2024, $0 in 2025, $0.21 in 2026, and $0.66 in 2027.

What is Caris Life Sciences’s revenue forecast?

Caris Life Sciences's average annual revenue forecast for its fiscal year ending in December 2023 is $421.94M, reflecting a 0% decrease from the reported - in 2022. The forecast for 2024 is $452.5M, followed by $330.09M for 2025, $939.25M for 2026, and $1.16B for 2027.

What is Caris Life Sciences’s net income forecast?

Caris Life Sciences's net income forecast for the fiscal year ending in December 2023 stands at $123.78M, representing a 0% decrease from the reported - in 2022. Projections indicate $-187M in 2024, $0 in 2025, $3.77M in 2026, and $10.23M in 2027.